Le Lézard
Classified in: Health
Subject: ACC

Photocure ASA - Correction: Annual general meeting held


OSLO, Norway, May 4, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00 hours (CET).

The minutes (corrected) from the general meeting setting out the resolved resolutions are attached hereto.

For further information, please contact:

Photocure 
CFO Erik Dahl
Tel: + 47 450 55 000
Email: [email protected]

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

The following files are available for download:

https://mb.cision.com/Main/17498/3763944/2033791.pdf

Release

https://mb.cision.com/Public/17498/3763944/9ce5f935d9b96fee.pdf

Photocure - Minutes from AGM 2023 ENG

https://mb.cision.com/Public/17498/3763944/9a71aff87f1efd21.pdf

Photocure - Minutes from AGM 2023 NOR

 

SOURCE Photocure


These press releases may also interest you

at 06:15
Karmanos Welcomes Wasif Saif, M.D., to Lead Phase 1 Clinical Trials
The Barbara Ann Karmanos Cancer Institute welcomes Wasif Saif, M.D., MBBS, as the new leader of the Phase 1 Clinical Trials Multidisciplinary Team and co-leader of the Gastrointestinal (GI) and Neuroendocrine Oncology Multidisciplinary Team...

at 06:07
Seed Health to Present New Clinical Data on 'DS-01® Daily Synbiotic' for Both Antibiotic Recovery and IBS at Digestive Disease Week 2024
Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two...

at 06:05
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
Arrowhead Pharmaceuticals, Inc. today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS)...

at 06:00
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel...

at 06:00
Study at Japan's Kameda Medical Center Demonstrates Excellent Outcomes for Ibex's AI-powered Solution in Diagnosing Prostate and Breast Cancer
Ibex Medical Analytics (Ibex), a global leader in AI-powered cancer diagnostics, and Kameda Medical Center (Kameda), a leading Japanese institute at the pinnacle of healthcare innovation, today announced the publication of a clinical study evaluating...

at 06:00
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director
HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg Hunt, former Australian Federal Minister for Health, to...

More news about Health...


News published on and distributed by: